Users Coming Off Anti-Obesity Injections Put On Weight Four Times Faster Compared to Those on Conventional Diets

New research indicates that patients who stop using new slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional lifestyle regimens.

Published data in a leading medical journal demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month after stopping.

"Individuals purchasing such drugs need to be cognizant of the risk of rapid rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.

This pace of regain implies a return to starting mass in about 18 months.

Analyzing Approaches

The research, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with older methods.

The team point out that individuals who lose weight through diet and exercise usually experience a slower weight regain—approximately 100 grams monthly—once they finish.

Understanding the Quick Rebound

Doctors believe the way of the drugs accounts for the amplified rebound.

The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.

"Stopping of this medication results in appetite is no longer kept in check, making excessive eating much more probable."

An Ongoing Condition?

The NHS recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.

Many experts say that, given the high risk of weight regain, the therapy might need to be life-long.

This perspective is echoed by pharmaceutical companies, who state that the results "highlight the persistent character of obesity," comparing it to managing conditions like high blood pressure.

Patient Accounts

People who have come off the medication explain a intense resurgence of cravings.

"It was like a switch that goes on and I was suddenly ravenous," said an individual.

The struggle is exacerbated if patients have not adopted permanent lifestyle or habit modifications during treatment.

Widespread Interest

Figures show that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.

• Use is more common among women than males.
• The middle-aged demographic shows the highest level of interest.
• A large proportion access the drugs through private healthcare rather than the NHS.

Finally, clinicians caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and long-term success likely depends on ongoing behavioural management.